nodes	percent_of_prediction	percent_of_DWPC	metapath
Pasireotide—SSTR1—SIDS Susceptibility Pathways—FEV—bone cancer	0.0888	0.0928	CbGpPWpGaD
Pasireotide—SSTR2—SIDS Susceptibility Pathways—FEV—bone cancer	0.0727	0.076	CbGpPWpGaD
Pasireotide—SSTR2—GPCRs, Other—GRM1—bone cancer	0.0379	0.0396	CbGpPWpGaD
Pasireotide—SSTR2—GPCRs, Other—SMO—bone cancer	0.0267	0.0279	CbGpPWpGaD
Pasireotide—SSTR3—G alpha (i) signalling events—RGS1—bone cancer	0.0261	0.0272	CbGpPWpGaD
Pasireotide—SSTR3—G alpha (i) signalling events—GRM4—bone cancer	0.0261	0.0272	CbGpPWpGaD
Pasireotide—SSTR1—G alpha (i) signalling events—RGS1—bone cancer	0.025	0.0261	CbGpPWpGaD
Pasireotide—SSTR1—G alpha (i) signalling events—GRM4—bone cancer	0.025	0.0261	CbGpPWpGaD
Pasireotide—SSTR5—G alpha (i) signalling events—GRM4—bone cancer	0.0222	0.0232	CbGpPWpGaD
Pasireotide—SSTR5—G alpha (i) signalling events—RGS1—bone cancer	0.0222	0.0232	CbGpPWpGaD
Pasireotide—SSTR2—G alpha (i) signalling events—GRM4—bone cancer	0.0205	0.0214	CbGpPWpGaD
Pasireotide—SSTR2—G alpha (i) signalling events—RGS1—bone cancer	0.0205	0.0214	CbGpPWpGaD
Pasireotide—SSTR3—GPCR ligand binding—GRM4—bone cancer	0.0158	0.0165	CbGpPWpGaD
Pasireotide—SSTR1—GPCR ligand binding—GRM4—bone cancer	0.0151	0.0158	CbGpPWpGaD
Pasireotide—SSTR3—GPCR ligand binding—GRM1—bone cancer	0.0137	0.0143	CbGpPWpGaD
Pasireotide—SSTR5—GPCR ligand binding—GRM4—bone cancer	0.0134	0.014	CbGpPWpGaD
Pasireotide—SSTR1—GPCR ligand binding—GRM1—bone cancer	0.0131	0.0137	CbGpPWpGaD
Pasireotide—SSTR2—GPCR ligand binding—GRM4—bone cancer	0.0124	0.0129	CbGpPWpGaD
Pasireotide—SSTR5—GPCR ligand binding—GRM1—bone cancer	0.0116	0.0122	CbGpPWpGaD
Pasireotide—SSTR2—GPCR ligand binding—GRM1—bone cancer	0.0107	0.0112	CbGpPWpGaD
Pasireotide—SSTR3—GPCR ligand binding—SMO—bone cancer	0.00964	0.0101	CbGpPWpGaD
Pasireotide—SSTR1—GPCR ligand binding—SMO—bone cancer	0.00924	0.00966	CbGpPWpGaD
Pasireotide—SSTR3—GPCR downstream signaling—GRM4—bone cancer	0.00892	0.00932	CbGpPWpGaD
Pasireotide—SSTR3—GPCR downstream signaling—RGS1—bone cancer	0.00892	0.00932	CbGpPWpGaD
Pasireotide—SSTR1—GPCR downstream signaling—GRM4—bone cancer	0.00855	0.00894	CbGpPWpGaD
Pasireotide—SSTR1—GPCR downstream signaling—RGS1—bone cancer	0.00855	0.00894	CbGpPWpGaD
Pasireotide—SSTR5—GPCR ligand binding—SMO—bone cancer	0.0082	0.00857	CbGpPWpGaD
Pasireotide—SSTR3—Signaling by GPCR—RGS1—bone cancer	0.0081	0.00846	CbGpPWpGaD
Pasireotide—SSTR3—Signaling by GPCR—GRM4—bone cancer	0.0081	0.00846	CbGpPWpGaD
Pasireotide—SSTR1—Signaling by GPCR—RGS1—bone cancer	0.00776	0.00811	CbGpPWpGaD
Pasireotide—SSTR1—Signaling by GPCR—GRM4—bone cancer	0.00776	0.00811	CbGpPWpGaD
Pasireotide—SSTR3—GPCR downstream signaling—GRM1—bone cancer	0.00773	0.00808	CbGpPWpGaD
Pasireotide—SSTR5—GPCR downstream signaling—GRM4—bone cancer	0.00758	0.00792	CbGpPWpGaD
Pasireotide—SSTR5—GPCR downstream signaling—RGS1—bone cancer	0.00758	0.00792	CbGpPWpGaD
Pasireotide—SSTR2—GPCR ligand binding—SMO—bone cancer	0.00757	0.00791	CbGpPWpGaD
Pasireotide—SSTR1—GPCR downstream signaling—GRM1—bone cancer	0.00741	0.00775	CbGpPWpGaD
Pasireotide—SSTR3—Signaling by GPCR—GRM1—bone cancer	0.00702	0.00734	CbGpPWpGaD
Pasireotide—SSTR1—SIDS Susceptibility Pathways—JUN—bone cancer	0.00702	0.00733	CbGpPWpGaD
Pasireotide—SSTR2—GPCR downstream signaling—GRM4—bone cancer	0.007	0.00731	CbGpPWpGaD
Pasireotide—SSTR2—GPCR downstream signaling—RGS1—bone cancer	0.007	0.00731	CbGpPWpGaD
Pasireotide—SSTR5—Signaling by GPCR—RGS1—bone cancer	0.00689	0.0072	CbGpPWpGaD
Pasireotide—SSTR5—Signaling by GPCR—GRM4—bone cancer	0.00689	0.0072	CbGpPWpGaD
Pasireotide—SSTR1—Signaling by GPCR—GRM1—bone cancer	0.00673	0.00704	CbGpPWpGaD
Pasireotide—SSTR5—GPCR downstream signaling—GRM1—bone cancer	0.00658	0.00687	CbGpPWpGaD
Pasireotide—SSTR2—Signaling by GPCR—GRM4—bone cancer	0.00636	0.00664	CbGpPWpGaD
Pasireotide—SSTR2—Signaling by GPCR—RGS1—bone cancer	0.00636	0.00664	CbGpPWpGaD
Pasireotide—SSTR2—GPCR downstream signaling—GRM1—bone cancer	0.00607	0.00634	CbGpPWpGaD
Pasireotide—SSTR5—Signaling by GPCR—GRM1—bone cancer	0.00597	0.00624	CbGpPWpGaD
Pasireotide—SSTR2—SIDS Susceptibility Pathways—JUN—bone cancer	0.00574	0.006	CbGpPWpGaD
Pasireotide—SSTR2—Signaling by GPCR—GRM1—bone cancer	0.00551	0.00576	CbGpPWpGaD
Pasireotide—SSTR3—GPCR downstream signaling—GNA11—bone cancer	0.00498	0.00521	CbGpPWpGaD
Pasireotide—SSTR3—Signaling by GPCR—SMO—bone cancer	0.00495	0.00517	CbGpPWpGaD
Pasireotide—SSTR3—Signaling Pathways—GRM4—bone cancer	0.00478	0.005	CbGpPWpGaD
Pasireotide—SSTR3—Signaling Pathways—RGS1—bone cancer	0.00478	0.005	CbGpPWpGaD
Pasireotide—SSTR1—GPCR downstream signaling—GNA11—bone cancer	0.00478	0.00499	CbGpPWpGaD
Pasireotide—SSTR1—Signaling by GPCR—SMO—bone cancer	0.00474	0.00496	CbGpPWpGaD
Pasireotide—SSTR1—Signaling Pathways—RGS1—bone cancer	0.00459	0.00479	CbGpPWpGaD
Pasireotide—SSTR1—Signaling Pathways—GRM4—bone cancer	0.00459	0.00479	CbGpPWpGaD
Pasireotide—SSTR3—Signaling by GPCR—GNA11—bone cancer	0.00453	0.00473	CbGpPWpGaD
Pasireotide—SSTR3—GPCR downstream signaling—IL3—bone cancer	0.00452	0.00472	CbGpPWpGaD
Pasireotide—SSTR1—Signaling by GPCR—GNA11—bone cancer	0.00434	0.00453	CbGpPWpGaD
Pasireotide—SSTR1—GPCR downstream signaling—IL3—bone cancer	0.00433	0.00453	CbGpPWpGaD
Pasireotide—SSTR5—GPCR downstream signaling—GNA11—bone cancer	0.00424	0.00443	CbGpPWpGaD
Pasireotide—SSTR5—Signaling by GPCR—SMO—bone cancer	0.00421	0.0044	CbGpPWpGaD
Pasireotide—SSTR3—Signaling Pathways—GRM1—bone cancer	0.00415	0.00433	CbGpPWpGaD
Pasireotide—SSTR3—Signaling by GPCR—IL3—bone cancer	0.0041	0.00429	CbGpPWpGaD
Pasireotide—SSTR5—Signaling Pathways—GRM4—bone cancer	0.00407	0.00425	CbGpPWpGaD
Pasireotide—SSTR5—Signaling Pathways—RGS1—bone cancer	0.00407	0.00425	CbGpPWpGaD
Pasireotide—SSTR1—Signaling Pathways—GRM1—bone cancer	0.00398	0.00416	CbGpPWpGaD
Pasireotide—SSTR1—Signaling by GPCR—IL3—bone cancer	0.00393	0.00411	CbGpPWpGaD
Pasireotide—SSTR2—GPCR downstream signaling—GNA11—bone cancer	0.00391	0.00409	CbGpPWpGaD
Pasireotide—SSTR2—Signaling by GPCR—SMO—bone cancer	0.00388	0.00406	CbGpPWpGaD
Pasireotide—SSTR5—Signaling by GPCR—GNA11—bone cancer	0.00385	0.00402	CbGpPWpGaD
Pasireotide—SSTR5—GPCR downstream signaling—IL3—bone cancer	0.00384	0.00401	CbGpPWpGaD
Pasireotide—SSTR2—Signaling Pathways—RGS1—bone cancer	0.00375	0.00392	CbGpPWpGaD
Pasireotide—SSTR2—Signaling Pathways—GRM4—bone cancer	0.00375	0.00392	CbGpPWpGaD
Pasireotide—SSTR2—Signaling by GPCR—GNA11—bone cancer	0.00355	0.00371	CbGpPWpGaD
Pasireotide—SSTR2—GPCR downstream signaling—IL3—bone cancer	0.00354	0.0037	CbGpPWpGaD
Pasireotide—SSTR5—Signaling Pathways—GRM1—bone cancer	0.00353	0.00369	CbGpPWpGaD
Pasireotide—SSTR5—Signaling by GPCR—IL3—bone cancer	0.00349	0.00365	CbGpPWpGaD
Pasireotide—SSTR2—Signaling Pathways—GRM1—bone cancer	0.00326	0.0034	CbGpPWpGaD
Pasireotide—SSTR2—Signaling by GPCR—IL3—bone cancer	0.00322	0.00336	CbGpPWpGaD
Pasireotide—SSTR3—Signaling Pathways—SMO—bone cancer	0.00292	0.00305	CbGpPWpGaD
Pasireotide—Amylase increased—Cisplatin—bone cancer	0.00292	0.0689	CcSEcCtD
Pasireotide—SSTR1—Signaling Pathways—SMO—bone cancer	0.0028	0.00293	CbGpPWpGaD
Pasireotide—SSTR3—Signaling Pathways—GNA11—bone cancer	0.00267	0.00279	CbGpPWpGaD
Pasireotide—SSTR1—Signaling Pathways—GNA11—bone cancer	0.00256	0.00268	CbGpPWpGaD
Pasireotide—SSTR5—Signaling Pathways—SMO—bone cancer	0.00249	0.0026	CbGpPWpGaD
Pasireotide—SSTR3—Signaling Pathways—ATF1—bone cancer	0.00249	0.0026	CbGpPWpGaD
Pasireotide—SSTR3—Signaling Pathways—IL3—bone cancer	0.00242	0.00253	CbGpPWpGaD
Pasireotide—SSTR1—Signaling Pathways—ATF1—bone cancer	0.00238	0.00249	CbGpPWpGaD
Pasireotide—SSTR1—Signaling Pathways—IL3—bone cancer	0.00232	0.00243	CbGpPWpGaD
Pasireotide—SSTR2—Signaling Pathways—SMO—bone cancer	0.00229	0.0024	CbGpPWpGaD
Pasireotide—SSTR5—Signaling Pathways—GNA11—bone cancer	0.00227	0.00238	CbGpPWpGaD
Pasireotide—SSTR5—Signaling Pathways—ATF1—bone cancer	0.00211	0.00221	CbGpPWpGaD
Pasireotide—SSTR2—Signaling Pathways—GNA11—bone cancer	0.0021	0.00219	CbGpPWpGaD
Pasireotide—SSTR3—Signaling Pathways—TGFBR2—bone cancer	0.00207	0.00217	CbGpPWpGaD
Pasireotide—SSTR5—Signaling Pathways—IL3—bone cancer	0.00206	0.00215	CbGpPWpGaD
Pasireotide—SSTR1—Signaling Pathways—TGFBR2—bone cancer	0.00199	0.00208	CbGpPWpGaD
Pasireotide—SSTR2—Signaling Pathways—ATF1—bone cancer	0.00195	0.00204	CbGpPWpGaD
Pasireotide—SSTR3—Signaling Pathways—IGF1R—bone cancer	0.00195	0.00204	CbGpPWpGaD
Pasireotide—SSTR2—Signaling Pathways—IL3—bone cancer	0.0019	0.00199	CbGpPWpGaD
Pasireotide—SSTR1—Signaling Pathways—IGF1R—bone cancer	0.00187	0.00195	CbGpPWpGaD
Pasireotide—SSTR5—Signaling Pathways—TGFBR2—bone cancer	0.00176	0.00184	CbGpPWpGaD
Pasireotide—Prothrombin level increased—Epirubicin—bone cancer	0.00174	0.0411	CcSEcCtD
Pasireotide—SSTR5—Signaling Pathways—IGF1R—bone cancer	0.00166	0.00173	CbGpPWpGaD
Pasireotide—SSTR2—Signaling Pathways—TGFBR2—bone cancer	0.00163	0.0017	CbGpPWpGaD
Pasireotide—Prothrombin level increased—Doxorubicin—bone cancer	0.00161	0.038	CcSEcCtD
Pasireotide—SSTR2—Signaling Pathways—IGF1R—bone cancer	0.00153	0.0016	CbGpPWpGaD
Pasireotide—SSTR3—Signaling Pathways—KIT—bone cancer	0.00141	0.00148	CbGpPWpGaD
Pasireotide—SSTR1—Signaling Pathways—KIT—bone cancer	0.00136	0.00142	CbGpPWpGaD
Pasireotide—SSTR3—Signaling Pathways—BRAF—bone cancer	0.00133	0.00139	CbGpPWpGaD
Pasireotide—SSTR3—Signaling by GPCR—EGFR—bone cancer	0.00129	0.00135	CbGpPWpGaD
Pasireotide—SSTR1—Signaling Pathways—BRAF—bone cancer	0.00127	0.00133	CbGpPWpGaD
Pasireotide—SSTR1—Signaling by GPCR—EGFR—bone cancer	0.00124	0.00129	CbGpPWpGaD
Pasireotide—SSTR5—Signaling Pathways—KIT—bone cancer	0.0012	0.00126	CbGpPWpGaD
Pasireotide—SSTR5—Signaling Pathways—BRAF—bone cancer	0.00113	0.00118	CbGpPWpGaD
Pasireotide—SSTR3—Signaling Pathways—MDM2—bone cancer	0.00111	0.00116	CbGpPWpGaD
Pasireotide—SSTR2—Signaling Pathways—KIT—bone cancer	0.00111	0.00116	CbGpPWpGaD
Pasireotide—SSTR5—Signaling by GPCR—EGFR—bone cancer	0.0011	0.00114	CbGpPWpGaD
Pasireotide—SSTR1—Signaling Pathways—MDM2—bone cancer	0.00107	0.00112	CbGpPWpGaD
Pasireotide—SSTR2—Signaling Pathways—BRAF—bone cancer	0.00104	0.00109	CbGpPWpGaD
Pasireotide—SSTR2—Signaling by GPCR—EGFR—bone cancer	0.00101	0.00106	CbGpPWpGaD
Pasireotide—SSTR3—Signaling Pathways—JUN—bone cancer	0.000968	0.00101	CbGpPWpGaD
Pasireotide—SSTR5—Signaling Pathways—MDM2—bone cancer	0.000947	0.00099	CbGpPWpGaD
Pasireotide—SSTR3—Signaling Pathways—MMP9—bone cancer	0.000942	0.000984	CbGpPWpGaD
Pasireotide—SSTR1—Signaling Pathways—JUN—bone cancer	0.000928	0.00097	CbGpPWpGaD
Pasireotide—Hypokalaemia—Cisplatin—bone cancer	0.000919	0.0217	CcSEcCtD
Pasireotide—Aspartate aminotransferase increased—Cisplatin—bone cancer	0.000909	0.0214	CcSEcCtD
Pasireotide—SSTR1—Signaling Pathways—MMP9—bone cancer	0.000903	0.000944	CbGpPWpGaD
Pasireotide—Nasopharyngitis—Cisplatin—bone cancer	0.000903	0.0213	CcSEcCtD
Pasireotide—SSTR2—Signaling Pathways—MDM2—bone cancer	0.000874	0.000913	CbGpPWpGaD
Pasireotide—SSTR5—Signaling Pathways—JUN—bone cancer	0.000823	0.00086	CbGpPWpGaD
Pasireotide—SSTR5—Signaling Pathways—MMP9—bone cancer	0.000801	0.000837	CbGpPWpGaD
Pasireotide—SSTR3—Signaling Pathways—EGFR—bone cancer	0.000761	0.000795	CbGpPWpGaD
Pasireotide—SSTR2—Signaling Pathways—JUN—bone cancer	0.00076	0.000794	CbGpPWpGaD
Pasireotide—SSTR2—Signaling Pathways—MMP9—bone cancer	0.000739	0.000772	CbGpPWpGaD
Pasireotide—SSTR1—Signaling Pathways—EGFR—bone cancer	0.00073	0.000763	CbGpPWpGaD
Pasireotide—Injection site reaction—Epirubicin—bone cancer	0.00071	0.0167	CcSEcCtD
Pasireotide—Injection site reaction—Doxorubicin—bone cancer	0.000657	0.0155	CcSEcCtD
Pasireotide—SSTR5—Signaling Pathways—EGFR—bone cancer	0.000647	0.000676	CbGpPWpGaD
Pasireotide—SSTR3—Signaling Pathways—TP53—bone cancer	0.000639	0.000668	CbGpPWpGaD
Pasireotide—Diabetes mellitus—Methotrexate—bone cancer	0.000637	0.015	CcSEcCtD
Pasireotide—Desmopressin—PTGS2—bone cancer	0.000635	1	CrCbGaD
Pasireotide—Alopecia—Cisplatin—bone cancer	0.000617	0.0146	CcSEcCtD
Pasireotide—SSTR1—Signaling Pathways—TP53—bone cancer	0.000613	0.00064	CbGpPWpGaD
Pasireotide—SSTR2—Signaling Pathways—EGFR—bone cancer	0.000597	0.000624	CbGpPWpGaD
Pasireotide—Diabetes mellitus—Epirubicin—bone cancer	0.000596	0.0141	CcSEcCtD
Pasireotide—Anaemia—Cisplatin—bone cancer	0.000562	0.0133	CcSEcCtD
Pasireotide—Diabetes mellitus—Doxorubicin—bone cancer	0.000552	0.013	CcSEcCtD
Pasireotide—SSTR5—Signaling Pathways—TP53—bone cancer	0.000543	0.000568	CbGpPWpGaD
Pasireotide—Hypoglycaemia—Epirubicin—bone cancer	0.000531	0.0125	CcSEcCtD
Pasireotide—Pain in extremity—Epirubicin—bone cancer	0.000519	0.0122	CcSEcCtD
Pasireotide—Myalgia—Cisplatin—bone cancer	0.000518	0.0122	CcSEcCtD
Pasireotide—Anxiety—Cisplatin—bone cancer	0.000516	0.0122	CcSEcCtD
Pasireotide—SSTR2—Signaling Pathways—TP53—bone cancer	0.000502	0.000524	CbGpPWpGaD
Pasireotide—Hypoglycaemia—Doxorubicin—bone cancer	0.000492	0.0116	CcSEcCtD
Pasireotide—Pain in extremity—Doxorubicin—bone cancer	0.00048	0.0113	CcSEcCtD
Pasireotide—Dry skin—Epirubicin—bone cancer	0.000475	0.0112	CcSEcCtD
Pasireotide—Abdominal pain upper—Epirubicin—bone cancer	0.000474	0.0112	CcSEcCtD
Pasireotide—Hypokalaemia—Epirubicin—bone cancer	0.000472	0.0111	CcSEcCtD
Pasireotide—Aspartate aminotransferase increased—Epirubicin—bone cancer	0.000467	0.011	CcSEcCtD
Pasireotide—Hypotension—Cisplatin—bone cancer	0.000464	0.0109	CcSEcCtD
Pasireotide—Nasopharyngitis—Epirubicin—bone cancer	0.000464	0.0109	CcSEcCtD
Pasireotide—Alanine aminotransferase increased—Epirubicin—bone cancer	0.000457	0.0108	CcSEcCtD
Pasireotide—Musculoskeletal discomfort—Cisplatin—bone cancer	0.000452	0.0107	CcSEcCtD
Pasireotide—Abdominal distension—Epirubicin—bone cancer	0.000451	0.0106	CcSEcCtD
Pasireotide—Influenza—Epirubicin—bone cancer	0.000448	0.0106	CcSEcCtD
Pasireotide—Dry skin—Doxorubicin—bone cancer	0.00044	0.0104	CcSEcCtD
Pasireotide—Abdominal pain upper—Doxorubicin—bone cancer	0.000438	0.0103	CcSEcCtD
Pasireotide—Hypokalaemia—Doxorubicin—bone cancer	0.000437	0.0103	CcSEcCtD
Pasireotide—Aspartate aminotransferase increased—Doxorubicin—bone cancer	0.000432	0.0102	CcSEcCtD
Pasireotide—Decreased appetite—Cisplatin—bone cancer	0.000431	0.0102	CcSEcCtD
Pasireotide—Nasopharyngitis—Doxorubicin—bone cancer	0.000429	0.0101	CcSEcCtD
Pasireotide—Alanine aminotransferase increased—Doxorubicin—bone cancer	0.000423	0.00998	CcSEcCtD
Pasireotide—Abdominal distension—Doxorubicin—bone cancer	0.000417	0.00984	CcSEcCtD
Pasireotide—Influenza—Doxorubicin—bone cancer	0.000415	0.00978	CcSEcCtD
Pasireotide—Hyperglycaemia—Epirubicin—bone cancer	0.000404	0.00953	CcSEcCtD
Pasireotide—Hyperglycaemia—Doxorubicin—bone cancer	0.000374	0.00882	CcSEcCtD
Pasireotide—Asthenia—Cisplatin—bone cancer	0.000356	0.0084	CcSEcCtD
Pasireotide—Oedema peripheral—Epirubicin—bone cancer	0.000353	0.00833	CcSEcCtD
Pasireotide—Diarrhoea—Cisplatin—bone cancer	0.00034	0.00801	CcSEcCtD
Pasireotide—Alopecia—Methotrexate—bone cancer	0.000339	0.00799	CcSEcCtD
Pasireotide—Oedema peripheral—Doxorubicin—bone cancer	0.000327	0.00771	CcSEcCtD
Pasireotide—Back pain—Methotrexate—bone cancer	0.000323	0.00761	CcSEcCtD
Pasireotide—Alopecia—Epirubicin—bone cancer	0.000317	0.00747	CcSEcCtD
Pasireotide—Vomiting—Cisplatin—bone cancer	0.000316	0.00744	CcSEcCtD
Pasireotide—Anaemia—Methotrexate—bone cancer	0.000308	0.00727	CcSEcCtD
Pasireotide—Back pain—Epirubicin—bone cancer	0.000302	0.00712	CcSEcCtD
Pasireotide—Vertigo—Methotrexate—bone cancer	0.0003	0.00707	CcSEcCtD
Pasireotide—Nausea—Cisplatin—bone cancer	0.000295	0.00695	CcSEcCtD
Pasireotide—Alopecia—Doxorubicin—bone cancer	0.000293	0.00692	CcSEcCtD
Pasireotide—Anaemia—Epirubicin—bone cancer	0.000289	0.00681	CcSEcCtD
Pasireotide—Arthralgia—Methotrexate—bone cancer	0.000284	0.0067	CcSEcCtD
Pasireotide—Myalgia—Methotrexate—bone cancer	0.000284	0.0067	CcSEcCtD
Pasireotide—Vertigo—Epirubicin—bone cancer	0.000281	0.00662	CcSEcCtD
Pasireotide—Back pain—Doxorubicin—bone cancer	0.000279	0.00659	CcSEcCtD
Pasireotide—Hypertension—Epirubicin—bone cancer	0.00027	0.00636	CcSEcCtD
Pasireotide—Anaemia—Doxorubicin—bone cancer	0.000267	0.0063	CcSEcCtD
Pasireotide—Myalgia—Epirubicin—bone cancer	0.000266	0.00627	CcSEcCtD
Pasireotide—Arthralgia—Epirubicin—bone cancer	0.000266	0.00627	CcSEcCtD
Pasireotide—Anxiety—Epirubicin—bone cancer	0.000265	0.00625	CcSEcCtD
Pasireotide—Vertigo—Doxorubicin—bone cancer	0.00026	0.00612	CcSEcCtD
Pasireotide—Hypotension—Methotrexate—bone cancer	0.000254	0.006	CcSEcCtD
Pasireotide—Hypertension—Doxorubicin—bone cancer	0.000249	0.00588	CcSEcCtD
Pasireotide—Musculoskeletal discomfort—Methotrexate—bone cancer	0.000248	0.00585	CcSEcCtD
Pasireotide—Insomnia—Methotrexate—bone cancer	0.000246	0.00581	CcSEcCtD
Pasireotide—Myalgia—Doxorubicin—bone cancer	0.000246	0.0058	CcSEcCtD
Pasireotide—Arthralgia—Doxorubicin—bone cancer	0.000246	0.0058	CcSEcCtD
Pasireotide—Anxiety—Doxorubicin—bone cancer	0.000245	0.00578	CcSEcCtD
Pasireotide—Hypotension—Epirubicin—bone cancer	0.000238	0.00562	CcSEcCtD
Pasireotide—Decreased appetite—Methotrexate—bone cancer	0.000237	0.00558	CcSEcCtD
Pasireotide—Fatigue—Methotrexate—bone cancer	0.000235	0.00554	CcSEcCtD
Pasireotide—Musculoskeletal discomfort—Epirubicin—bone cancer	0.000232	0.00547	CcSEcCtD
Pasireotide—Insomnia—Epirubicin—bone cancer	0.000231	0.00543	CcSEcCtD
Pasireotide—Gastrointestinal pain—Methotrexate—bone cancer	0.000223	0.00525	CcSEcCtD
Pasireotide—Decreased appetite—Epirubicin—bone cancer	0.000222	0.00522	CcSEcCtD
Pasireotide—Hypotension—Doxorubicin—bone cancer	0.00022	0.0052	CcSEcCtD
Pasireotide—Fatigue—Epirubicin—bone cancer	0.00022	0.00518	CcSEcCtD
Pasireotide—Constipation—Epirubicin—bone cancer	0.000218	0.00514	CcSEcCtD
Pasireotide—Abdominal pain—Methotrexate—bone cancer	0.000215	0.00508	CcSEcCtD
Pasireotide—Musculoskeletal discomfort—Doxorubicin—bone cancer	0.000215	0.00507	CcSEcCtD
Pasireotide—Insomnia—Doxorubicin—bone cancer	0.000213	0.00503	CcSEcCtD
Pasireotide—Gastrointestinal pain—Epirubicin—bone cancer	0.000208	0.00491	CcSEcCtD
Pasireotide—Decreased appetite—Doxorubicin—bone cancer	0.000205	0.00483	CcSEcCtD
Pasireotide—Fatigue—Doxorubicin—bone cancer	0.000203	0.00479	CcSEcCtD
Pasireotide—Constipation—Doxorubicin—bone cancer	0.000202	0.00475	CcSEcCtD
Pasireotide—Abdominal pain—Epirubicin—bone cancer	0.000201	0.00475	CcSEcCtD
Pasireotide—Asthenia—Methotrexate—bone cancer	0.000195	0.00461	CcSEcCtD
Pasireotide—Gastrointestinal pain—Doxorubicin—bone cancer	0.000193	0.00455	CcSEcCtD
Pasireotide—Pruritus—Methotrexate—bone cancer	0.000193	0.00454	CcSEcCtD
Pasireotide—Abdominal pain—Doxorubicin—bone cancer	0.000186	0.0044	CcSEcCtD
Pasireotide—Diarrhoea—Methotrexate—bone cancer	0.000186	0.00439	CcSEcCtD
Pasireotide—Asthenia—Epirubicin—bone cancer	0.000183	0.00431	CcSEcCtD
Pasireotide—Pruritus—Epirubicin—bone cancer	0.00018	0.00425	CcSEcCtD
Pasireotide—Dizziness—Methotrexate—bone cancer	0.00018	0.00425	CcSEcCtD
Pasireotide—Diarrhoea—Epirubicin—bone cancer	0.000174	0.00411	CcSEcCtD
Pasireotide—Vomiting—Methotrexate—bone cancer	0.000173	0.00408	CcSEcCtD
Pasireotide—Headache—Methotrexate—bone cancer	0.000171	0.00402	CcSEcCtD
Pasireotide—Asthenia—Doxorubicin—bone cancer	0.000169	0.00399	CcSEcCtD
Pasireotide—Dizziness—Epirubicin—bone cancer	0.000169	0.00397	CcSEcCtD
Pasireotide—Pruritus—Doxorubicin—bone cancer	0.000167	0.00393	CcSEcCtD
Pasireotide—Vomiting—Epirubicin—bone cancer	0.000162	0.00382	CcSEcCtD
Pasireotide—Nausea—Methotrexate—bone cancer	0.000162	0.00381	CcSEcCtD
Pasireotide—Diarrhoea—Doxorubicin—bone cancer	0.000161	0.0038	CcSEcCtD
Pasireotide—Headache—Epirubicin—bone cancer	0.00016	0.00376	CcSEcCtD
Pasireotide—Dizziness—Doxorubicin—bone cancer	0.000156	0.00368	CcSEcCtD
Pasireotide—Nausea—Epirubicin—bone cancer	0.000151	0.00357	CcSEcCtD
Pasireotide—Vomiting—Doxorubicin—bone cancer	0.00015	0.00354	CcSEcCtD
Pasireotide—Headache—Doxorubicin—bone cancer	0.000148	0.00348	CcSEcCtD
Pasireotide—Nausea—Doxorubicin—bone cancer	0.00014	0.0033	CcSEcCtD
